12/20/2023 0 Comments Silverback therapeutics news![]() ![]() The Merger is intended to qualify as a tax-free reorganization for U.S. ![]() Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into ARS, with ARS surviving the Merger as a wholly owned subsidiary of Silverback (the “ Merger”). On July 21, 2022, Silverback Therapeutics, Inc., a Delaware corporation (“ Silverback”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement”) with ARS Pharmaceuticals, Inc., a Delaware corporation (“ ARS”), a biopharmaceutical company focused on the development of neffy, a needle-free epinephrine nasal spray, for the emergency treatment of Type I allergic reactions, and Sabre Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Silverback (“ Merger Sub”). ☐Įntry into a Material Definitive Agreement. ![]() ![]() If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Securities registered pursuant to Section 12(b) of the Act:Ĭommon Stock, $0.0001 par value per share Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) The Kirkland team was led by corporate partners Dan Vaczy and Christian Atwood, tax partner Vincent Thorn, and investment funds partner Amala Ejikeme and associate Anna Alexandrou.Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Upon stockholder approval, the combined company is expected to operate under the name ARS Pharmaceuticals and trade on the Nasdaq Capital Market under the ticker symbol “SPRY.” The merger is currently expected to close in the fourth quarter of 2022. The combined company is expected to have approximately $265 million in cash, cash equivalents and marketable securities at closing. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. (ARS), under which ARS will merge with Silverback in an all-stock transaction. (Silverback), and ARS Pharmaceuticals, Inc. Kirkland & Ellis advised Nextech, a global, cancer therapeutics-focused venture capital firm, in connection with a definitive agreement between its portfolio company, Silverback Therapeutics, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |